Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease

Metabolism: Clinical and Experimental

Volumn 51, Issue 7, 2002, Pages 881-886

  Elian, Kelly M ^a   Hoffer, L John ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEMINAL C FORTIS; CYANOCOBALAMIN; DIAVITE; FOLIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN; METHYLMALONIC ACID; PYRIDOXINE; VITAMIN B GROUP;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLIC ACID BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; VEIN THROMBOSIS; VITAMIN BLOOD LEVEL;

EID: 0036064503     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.32800     Document Type: Article

References (54)

1. Homocysteine and atherothrombosis
2. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
3. Total homocysteine and cardiovascular disease
4. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
5. Homocysteine and its disulfide derivatives: A suggested consensus terminology
6. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels
7. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
8. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
9. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage disease
10. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
11. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study
12. Disorders of transsulfuration
13. Homocysteine and vascular disease
14. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
15. The role of homocysteine in end-stage renal disease
16. Hyperhomocysteinemia in chronic renal disease
17. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease
18. 12
19. 12 deficiency
20. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
21. Novel reductant for determination of total plasma homocysteine
22. Determination of total homocysteine in human plasma by isocratic high-performance liquid chromatography
23. 12 reduces hyperhomocysteinemia in end-stage renal disease
24. Determination of methylmalonic acid in biological fluids by mass spectrometry
25. Serum methylmalonic acid in uraemia
26. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation
27. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
28. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
29. Response of hyper-homocysteinemia to folic acid supplementation in patiens with end-stage renal disease
30. Treatment with different doses of folic acid in haemodialysis patients: Effects on folate distribution and aminothiol concentrations
31. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
32. Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins
33. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients
34. Water soluble vitamins in chronic hemodialysis patients and need for supplementation
35. A tale of two homocysteines - And two hemodialysis units
36. 12 levels and nerve conduction velocities in patients undergoing maintenance hemodialysis
37. Prevention of nitro-prusside-induced cyanide toxicity with hydroxocobalamin
38. Hydroxocobalamin vs cobalt toxicity on rat cardiac and diaphragmatic muscles
39. Pharmacokinetics of hydroxocobalamin in smoke inhalation victims
40. Biochemical and clinical response to hydroxocobalamin versus cyanocobalamin treatment in patients with methylmalonic acidemia and homocystinuria (cblC)
41. Homocysteine metabolism in renal failure
42. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria
43. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations
44. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients
45. Hypervitaminosis B12 in maintenance hemodialysis patients receiving massive supplementation of vitamin B12
46. Cytotoxic activity of cobalamin in cultured malignant and nonmalignant cells
47. Statistics notes: Blinding in clinical trials and other studies
48. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators
49. Comparison of evidence of treatment effects in randomized and nonrandomized studies
50. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
51. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
52. 12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia
53. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients